Abstract
Asthma is a prevalent pulmonary disease that affects nearly 300 million people worldwide and imposes a substantial economic burden. While medication can effectively control symptoms in some patients, severe asthma attacks, driven by airway-inflammation induced by environmental and infectious exposures, continue to be a major cause of asthma-related mortality. Heterogenous phenotypes of asthma include type 2 (T2) and non-T2 asthma. Non-T2 asthma is often observed in patients with severe and/or steroid-resistant asthma. This review will cover the molecular mechanisms, clinical phenotypes, causes and promising treatment of non-T2 severe asthma. Specifically, we will discuss the signaling pathways for non-T2 asthma including the activation of inflammasomes, interferon responses, and IL-17 pathways, and their contributions to the subtypes, progression, and severity of non-T2 asthma. Understanding the molecular mechanisms and genetic determinants underlying non-T2 asthma could form the basis for precision medicine in severe asthma treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.